Ideal HRT Regimen for Primary Ovarian Insufficiency

Estrogen Component

The European Society for Human Reproduction and Embryology (ESHRE) recommends transdermal 17β-estradiol as the preferred estrogen formulation because it mimics physiological serum estradiol concentrations, avoids hepatic first-pass effect, minimizes impact on hemostatic factors, and provides more beneficial effects on lipid profiles, inflammation markers, and blood pressure 3
The American College of Obstetricians and Gynecologists (ACOG) supports the use of transdermal 17β-estradiol, which is more effective in achieving peak bone mineral density compared to ethinylestradiol 3
Transdermal 17β-estradiol is the preferred delivery method in hypertensive women with POI, as recommended by the European Society of Cardiology 1
The recommended dosage is 50-100 μg of transdermal 17β-estradiol daily, according to the Endocrine Society 3
17β-estradiol is preferred over ethinylestradiol or conjugated equine estrogens, as stated by the North American Menopause Society 1, 2

Progestogen must be given in combination with estrogen therapy to protect the endometrium in women with an intact uterus, as recommended by the American College of Obstetricians and Gynecologists (ACOG) 1
Micronized natural progesterone (MP) is recommended because it minimizes hormone-related cardiovascular risks, has neutral or beneficial effects on blood pressure, and shows one of the best safety profiles in terms of thrombotic risk, according to the European Society for Human Reproduction and Embryology (ESHRE) 3
The recommended dosage is 100-200 mg/day of oral micronized progesterone during 12-14 days of the month, as stated by the Endocrine Society 1
Alternative progestins include dydrogesterone, listed in ESHRE guidelines, and medroxyprogesterone acetate (MPA), which has the strongest evidence for endometrial protection but may negatively impact cardiovascular risk, according to the European Society of Cardiology 3

A sequential/cyclic regimen is generally recommended as it allows earlier recognition of potential pregnancy and provides adequate endometrial protection, as stated by the American College of Obstetricians and Gynecologists (ACOG) 1, 3
Continuous combined regimen is an alternative that prevents withdrawal bleeding, according to the North American Menopause Society 3

HRT should be continued at least until the average age of natural menopause (50-51 years), as recommended by the Endocrine Society 4
Regular annual clinical reviews are recommended to assess compliance, according to the European Society for Human Reproduction and Embryology (ESHRE) 1

For women seeking contraception, combined oral contraceptives (COCs) may be considered, though they contain higher hormone doses than HRT, as stated by the American College of Obstetricians and Gynecologists (ACOG) 3
Spontaneous ovulation and conception can occur in POI (20-25% and 5-10% respectively), according to the European Society of Human Reproduction and Embryology (ESHRE) 3
For women with hypertension, transdermal estradiol is strongly preferred, as recommended by the European Society of Cardiology 1
HRT has not been found to increase breast cancer risk in women with POI before the age of natural menopause, according to the American College of Obstetricians and Gynecologists (ACOG) 1

Annual clinical review focusing on compliance is recommended, as stated by the Endocrine Society 1
Cardiovascular risk assessment (at least blood pressure, weight, and smoking status) annually is recommended, according to the European Society of Cardiology 4
No routine monitoring tests are required but may be prompted by specific symptoms, as stated by the American College of Obstetricians and Gynecologists (ACOG) 1

Using ethinylestradiol-containing contraceptives instead of 17β-estradiol for HRT is not recommended, as they have higher thrombotic risk and less favorable metabolic profiles, according to the European Society for Human Reproduction and Embryology (ESHRE) 3
Discontinuing HRT prematurely (before age of natural menopause) can increase risks of osteoporosis, cardiovascular disease, and urogenital atrophy, as stated by the Endocrine Society 1
Failing to add progestogen in women with an intact uterus increases risk of endometrial hyperplasia and cancer, according to the American College of Obstetricians and Gynecologists (ACOG) 1
Using inadequate doses that don't achieve physiological estrogen levels may not provide adequate protection against long-term health consequences, as recommended by the European Society for Human Reproduction and Embryology (ESHRE) 3